BeiGene, Ltd. (BGNE) Reaches $157.10 After 8.00% Up Move; Silchester International Investors Llp Has Decreased Its Sk Telecom LTD (SKM) Stake

March 14, 2018 - By reb123z

The stock of BeiGene, Ltd. (NASDAQ:BGNE) is a huge mover today! The stock increased 1.04% or $1.62 during the last trading session, reaching $157.1. About 244,392 shares traded. BeiGene, Ltd. (NASDAQ:BGNE) has risen 36.36% since March 14, 2017 and is uptrending. It has outperformed by 19.66% the S&P500.The move comes after 7 months positive chart setup for the $8.36 billion company. It was reported on Mar, 14 by We have $169.67 PT which if reached, will make NASDAQ:BGNE worth $668.64M more.

Silchester International Investors Llp decreased Sk Telecom Ltd (SKM) stake by 6.08% reported in 2017Q3 SEC filing. Silchester International Investors Llp sold 929,402 shares as Sk Telecom Ltd (SKM)’s stock rose 11.01%. The Silchester International Investors Llp holds 14.36 million shares with $353.16 million value, down from 15.29 million last quarter. Sk Telecom Ltd now has $15.17B valuation. The stock decreased 0.25% or $0.06 during the last trading session, reaching $24.24. About 212,538 shares traded. SK Telecom Co., Ltd. (NYSE:SKM) has risen 24.69% since March 14, 2017 and is uptrending. It has outperformed by 7.99% the S&P500.

Among 5 analysts covering SK Telecom (NYSE:SKM), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. SK Telecom had 5 analyst reports since November 2, 2015 according to SRatingsIntel. JP Morgan downgraded the shares of SKM in report on Monday, November 2 to “Neutral” rating. The rating was downgraded by Macquarie Research on Tuesday, October 25 to “Neutral”. On Friday, December 1 the stock rating was upgraded by Citigroup to “Buy”. The rating was downgraded by HSBC to “Hold” on Wednesday, April 27. CLSA upgraded SK Telecom Co., Ltd. (NYSE:SKM) on Monday, October 24 to “Buy” rating.

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company has market cap of $8.36 billion. The companyÂ’s clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. It currently has negative earnings. The Company’s preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.

Analysts await BeiGene, Ltd. (NASDAQ:BGNE) to report earnings on May, 9. They expect $-1.94 EPS, down 52.76% or $0.67 from last year’s $-1.27 per share. After $-2.19 actual EPS reported by BeiGene, Ltd. for the previous quarter, Wall Street now forecasts -11.42% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: